HC Wainwright Analysts Decrease Earnings Estimates for Myomo

Myomo, Inc. (NYSEAMERICAN:MYO) – Analysts at HC Wainwright cut their Q2 2025 earnings per share estimates for shares of Myomo in a research note issued on Thursday, May 8th. HC Wainwright analyst S. Lee now anticipates that the company will earn ($0.11) per share for the quarter, down from their previous estimate of ($0.06). HC Wainwright currently has a “Buy” rating and a $9.50 target price on the stock. The consensus estimate for Myomo’s current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Myomo’s Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at $0.10 EPS, FY2025 earnings at ($0.15) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.08) EPS, FY2026 earnings at $0.06 EPS and FY2027 earnings at $0.25 EPS.

Other research analysts have also issued research reports about the company. Ascendiant Capital Markets increased their target price on Myomo from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, March 17th. Alliance Global Partners reissued a “buy” rating on shares of Myomo in a research report on Tuesday, March 11th. Finally, Craig Hallum decreased their target price on Myomo from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $9.50.

Myomo Price Performance

Shares of NYSEAMERICAN:MYO opened at $3.20 on Monday. Myomo has a 52-week low of $2.76 and a 52-week high of $7.17. The company has a market cap of $96.80 million, a price-to-earnings ratio of -13.91 and a beta of 1.68. The stock has a 50 day moving average price of $4.78.

Hedge Funds Weigh In On Myomo

Institutional investors and hedge funds have recently modified their holdings of the company. Soleus Capital Management L.P. bought a new position in Myomo in the 4th quarter worth $5,796,000. AIGH Capital Management LLC raised its holdings in Myomo by 21.7% in the 4th quarter. AIGH Capital Management LLC now owns 3,381,567 shares of the company’s stock worth $21,777,000 after purchasing an additional 602,719 shares during the period. Portolan Capital Management LLC bought a new position in Myomo in the 4th quarter worth $2,446,000. Manatuck Hill Partners LLC bought a new stake in Myomo during the fourth quarter valued at about $1,582,000. Finally, Thompson Siegel & Walmsley LLC bought a new stake in Myomo during the fourth quarter valued at about $1,288,000. 44.99% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Myomo news, Director Thomas F. Kirk bought 7,400 shares of the business’s stock in a transaction on Thursday, March 13th. The shares were acquired at an average cost of $5.00 per share, for a total transaction of $37,000.00. Following the purchase, the director now owns 255,933 shares in the company, valued at approximately $1,279,665. This trade represents a 2.98% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Harry Kovelman sold 30,000 shares of the firm’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $5.50, for a total value of $165,000.00. Following the completion of the transaction, the insider now owns 97,973 shares in the company, valued at approximately $538,851.50. This trade represents a 23.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.54% of the stock is currently owned by company insiders.

Myomo Company Profile

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.